Comparative pharmacokinetics of rVIII ‐SingleChain and octocog alfa (Advate ® ) in patients with severe haemophilia A-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative pharmacokinetics of rVIII ‐SingleChain and octocog alfa (Advate ® ) in patients with severe haemophilia A

Published:2016-07-19 Issue:5 Volume:22 Page:730-738
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Klamroth R.¹,Simpson M.²,Depka‐Prondzinski M.³,Gill J. C.⁴,Morfini M.⁵,Powell J. S.⁶,Santagostino E.⁷,Davis J.⁸,Huth‐Kühne A.⁹,Leissinger C.¹⁰,Neumeister P.¹¹,Bensen‐Kennedy D.¹²,Feussner A.¹³,Limsakun T.¹²,Zhou M.¹²,Veldman A.¹³,St. Ledger K.¹²,Blackman N.¹²,Pabinger I.¹⁴

Affiliation:

1. Department for Internal Medicine Vascular Medicine and Haemostaseology Vivantes Klinikum Berlin Friedrichshain Germany

2. Rush University Medical Center Chicago IL USA

3. Werlhof Institut Hannover Germany

4. Medical College of Wisconsin and Blood Center of Wisconsin Milwaukee WI USA

5. Ospedaliero Universitaria Careggi Firenze Italy

6. Hemophilia Treatment Center UC Davis Sacramento CA USA

7. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico Milano Italy

8. University of Miami Hemophilia Treatment Center Miami FL USA

9. Hämophiliezentrum und Gerinnungsambulanz SRH Kurpfalzkrankenhaus Heidelberg Germany

10. Louisiana Center for Bleeding and Clotting Disorders New Orleans LA USA

11. Klinische Abteilung für Hämatologie Medizinische Universität of Graz Graz Austria

12. Clinical R&D CSL Behring King of Prussia PA USA

13. Clinical R&D CSL Behring Marburg Germany

14. Clinical Division of Hematology and Hemostaseology Department of Medicine I Medical University of Vienna Vienna Austria

Funder

CSL Behring

Baxter International

Bayer

Pfizer

Novo Nordisk

Roche

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12985

Reference23 articles.

1. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

2. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

3. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

4. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

5. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and challenges in the purification of recombinant coagulation factors: A review;Journal of Chromatography A;2024-02

2. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

3. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A;Blood Reviews;2023-12

4. Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects;Annals of Hematology;2023-11-11

5. Effects of PK‐guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A;Haemophilia;2023-08-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3